Adusumilli Prasad S, Stiles Brendon M, Chan Mei-Ki, Chou Ting-Chao, Wong Richard J, Rusch Valerie W, Fong Yuman
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Ann Thorac Surg. 2005 Aug;80(2):409-16; discussion 416-7. doi: 10.1016/j.athoracsur.2005.01.048.
Replication-competent oncolytic herpes simplex viruses with deletion of the gamma(1)34.5 gene preferentially replicate in and kill malignant cells. The gamma(1)34.5 gene codes for ICP 34.5, a protein that enhances viral replication, and is homologous to growth arrest and DNA damage protein 34 (GADD34), a radiation-inducible DNA repair gene. We hypothesized that radiation therapy may potentiate efficacy of oncolytic viral therapy by upregulating GADD34 and promoting viral replication.
The A549 and H1299 lung cancer cell lines were infected with NV1066, an oncolytic herpes simplex virus, at multiplicities of infection (number of viral particles per tumor cell) of 0.1 to 0.5 in vitro with radiation (2 to 10 Gy) or without radiation. Viral replication was determined by plaque assay, cell-to-cell spread was determined by flow cytometry, cell kill was determined by lactate dehydrogenase assay, and GADD34 induction was determined by real-time reverse transcription-polymerase chain reaction and Western blot method. Evidence of synergistic cytotoxicity dependence with GADD34 induction is further confirmed by small inhibitory RNA inhibition of GADD34 expression.
Using both the isobologram method and combination index method of Chou and Talalay, significant synergism was demonstrated between radiation therapy and NV1066 both in vitro and in vivo. As a result of such synergism, a dose reduction for each agent (2- to 6,000-fold) can be accomplished for a wide range of therapeutic effect levels without sacrificing tumor cell kill. This effect is correlated with increased GADD34 expression and inhibited by transfection of small inhibitory RNA directed against GADD34.
These data provide the cellular basis for the clinical investigation of combined use of radiation therapy with oncolytic herpes simplex virus therapy in the treatment of lung cancer to achieve synergistic efficacy while minimizing dosage and toxicity.
缺失γ(1)34.5基因的具有复制能力的溶瘤单纯疱疹病毒优先在恶性细胞中复制并将其杀死。γ(1)34.5基因编码ICP 34.5,一种增强病毒复制的蛋白质,它与生长停滞和DNA损伤蛋白34(GADD34)同源,后者是一种辐射诱导的DNA修复基因。我们推测放射治疗可能通过上调GADD34和促进病毒复制来增强溶瘤病毒治疗的疗效。
将A549和H1299肺癌细胞系在体外以感染复数(每个肿瘤细胞的病毒颗粒数)0.1至0.5用溶瘤单纯疱疹病毒NV1066进行感染,分为有辐射(2至10 Gy)组和无辐射组。通过噬斑测定法确定病毒复制,通过流式细胞术确定细胞间传播,通过乳酸脱氢酶测定法确定细胞杀伤,通过实时逆转录-聚合酶链反应和蛋白质印迹法确定GADD34的诱导。通过小干扰RNA抑制GADD34表达进一步证实了与GADD34诱导相关的协同细胞毒性依赖性证据。
使用Chou和Talalay的等效线图法和联合指数法,在体外和体内均证明放射治疗与NV1066之间存在显著的协同作用。由于这种协同作用,在不牺牲肿瘤细胞杀伤效果的情况下,对于广泛的治疗效果水平,每种药物的剂量可降低(2至6000倍)。这种效应与GADD34表达增加相关,并被针对GADD34的小干扰RNA转染所抑制。
这些数据为放射治疗与溶瘤单纯疱疹病毒治疗联合用于肺癌治疗以实现协同疗效同时最小化剂量和毒性的临床研究提供了细胞基础。